Random Posts
- Herbs That Cure Diabetes - A Must Read For Diabetics
- Think You Understand Diabetes?
- Uncover the Best Cures For Type 1 Diabetes
- Can You Reverse Diabetes Type 2 With Proper Meal Planning?
- What Should People With Type 2 Diabetes Be Eating?
- What Causes Diabetes Nerve Damage?
- What is Gestational Diabetes and How Can it Affect Your Baby
- How to Choose Foods That Lower Your Blood Sugar
- Best Resources For Free Diabetic Strips and Supplies to Your Doorstep
Prescription Diabetes Drugs
MCP1 variant linked to elevated carotid IMT in Type 2 diabetics]]>
Posted by admin in Prescription Diabetes Drugs on December 16th, 2010
A variant in the monocyte chemoattractant protein-1 gene (MCP1) could help identify patients with Type 2 diabetes who are at increased risk for developing carotid atherosclerosis, say researchers.
“MCP1 is a potent chemokine and plays an important role in cardiovascular diseases,” explain Sachiko Yuasa (Keio University School of Medicine, Tokyo, Japan) and colleagues.
Such diseases are important causes of morbidity and mortality in patients with Type 2 diabetes. In this study, Yuasa and team assessed whether genotype of the MCP1 A-2518G single nucleotide polymorphism (SNP) was related to the development of carotid atherosclerosis in 303 Japanese patients, aged 68 years on average, with Type 2 diabetes.
The researchers assessed for the presence of subclinical atherosclerosis by measuring carotid intima-media thickness (IMT) in the participants using ultrasonography.
As reported in the journal Diabetes Research and Clinical Practice, the researchers found that patients who were A-2518G G allele carriers had significantly greater carotid IMT than AA homozygotes, at 0.84 versus 0.70 mm.
Factors associated with carotid IMT included age, systolic blood pressure, low-density lipoprotein cholesterol, having the G allele of A-2518G, and level of glycated hemoglobin (HbA1c).
Following multiple regression analysis, the G allele of A-2518G was the third strongest determinant of carotid IMT, subsequent to age and systolic blood pressure, in patients with Type 2 diabetes.
“Although medical therapy targeting MCP1 has not yet been established, from our findings about the strong correlation between the MCP1 polymorphism and atherosclerosis in this study, we suggest that MCP-1 may be a potential therapeutic target,” conclude Yuasa et al.
“These data suggest that in patients with Type 2 diabetes, the MCP1 A-2518G polymorphism may be helpful to predict atherosclerosis progression and determine the need for intensive medical therapy for atherosclerosis.”
MedWire (www.medwire-news.md) is an independent clinical news service provided by Current Medicine Group, a part of Springer Science+Business Media. © Current Medicine Group Ltd; 2009
- Type 2 Diabetes - A Brief Explanation
- If You Knew This, Diabetes Symptoms Would Not Go Unnoticed
- Garlic Helps Beat Diabetes Naturally - Control Blood Sugar
- Microscopic Labeling - What You Cannot Read Can Hurt Your Blood Sugars
- Gestational Diabetes Diet - A Sample Plan
- Controlling You Diabetes - A Chore That Must Not Be Forgotten
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.